Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells

Acta Diabetologica

Volumn 49, Issue 1 SUPPL., 2012, Pages

  Pala, Laura ^a,b   Pezzatini, Anna ^a   Dicembrini, Ilaria ^a   Ciani, Silvia ^a   Gelmini, Stefania ^a   Vannelli, Barbara Gabriella ^a   Cresci, Barbara ^a,b   Mannucci, Edoardo ^b   Rotella, Carlo Maria ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b AOUC Careggi   (Italy)

Author keywords

DPP 4; Endothelial cells; Metformin; Rosiglitazone

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; MESSENGER RNA; METFORMIN; ROSIGLITAZONE;

ADULT; AORTA; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; MACROVASCULAR ENDOTHELIAL CELL; MICROVASCULAR ENDOTHELIAL CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM; ANTIBODY SPECIFICITY; CELL CULTURE; CELL LINE; COMPARATIVE STUDY; CYTOLOGY; DERMIS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; VASCULARIZATION;

AORTA; BLOOD GLUCOSE; CELL LINE; CELLS, CULTURED; DERMIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYPERGLYCEMIA; MICROVESSELS; ORGAN SPECIFICITY;

EID: 84878895774     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-010-0195-3     Document Type: Article

References (20)

1. Holst JJ, Deacon CF (1998) Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663-1670
2. Dubový P, Kukletová MA (1992) Histochemical study by light and electron microscopy of the distribution of dipeptidyl peptidase-IV activity in the human dental pulp. Arch Oral Biol 37(1):1-6
3. Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1-(7-36) amide, peptide histidine methionine, and is responsible for their degradation in human serum. Eur J Biochem 214:829-835
4. Augustyns K, Bal G, Thonus G, Belyaev A, Zhang XM, Bollaert W, Lambeir AM, Durinx C, Goossens F, Haemers A (1998) The unique properties of dipeptidyl-peptidase IV (DPP IV/CD 26) and the therapeutic potential of DPP-IV inhibitors. Curr Med Chem 6:311-327
5. Meneilly GS, Demuth HU, McIntosh CH, Pederson RA (2000) Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med 17:346-350
6. Visboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentration of intact biologically active glucagon-like peptide-1 in type 2 diabetic patients. Diabetes 50:609-613
7. Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I, Cremasco F, Ognibene A, Rotella CM (2005) Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 48(6):1168-1172
8. Pala L, Mannucci E, Pezzatini A, Ciani S, Sardi J, Raimondi L, Ognibene A, Cappadona A, Vannelli BG, Rotella CM (2003) Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 310:28-31
9. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Fanelli A, Messeri G, Rotella CM (2000) Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Diabet Med 17(10):713
10. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Messeri G, Rotella CM (2001) Effects of metformin on glucagon-like peptide-1 (GLP-1) and leptin levels in obese non-diabetic subjects. Diabetes Care 24:489-494
11. Lindsay JR, Duffy NA, McKillop AM, Ardill J, O'Harte FP, Flatt PR, Bell PM (2005) Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med 22(5):654-657
12. Green BD, Irwin N, Duffy NA, Gault VA, O'harte FP, Flatt PR (2006) Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 547(1-3):192-199
13. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I (2002) Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 298(5):779-784
14. Hinke SA, Kühn-Wache K, Hoffmann T, Pederson RA, McIntosh CH, Demuth HU (2002) Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 291(5):1302-1308
15. Duffy NA, Green BD, Irwin N, Gault VA, McKillop AM, O'Harte FP, Flatt PR (2007) Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. Eur J Pharmacol 568(1-3):278-286
16. Rotella CM, Giannini S, Galli G, Cresci B, Tanini A (1996) Role of endothelial cells in the pathogenesis of diabetic microangiopathy DNM 9:273-289
17. Benvenuti S, Cellai I, Luciani P, Deledda C, Baglioni S, Giuliani C, Saccardi R, Mazzanti B, Dal Pozzo S, Mannucci E, Peri A, Serio M (2007) Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest 30(9):RC26-RC30
18. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real time quantitative PCR and the 2 - ΔΔCt. Methods 25:402-408
19. Durinx C, Neels H, Van der Auwera JC, Naelaerts K, Scharpe S, De Meester I (2001) Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin Chem Lab Med 39:155-158
20. Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S, Pezzatini A, Brogi M, Dicembrini I, Cremasco F, Messeri G, Rotella CM (2004) Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab 17(6):336-342